Cargando…
Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis
Therapy for light chain amyloidosis (AL) continues to evolve, and a new standard of care for the disease is rapidly forming. The risk of early death however, mainly from cardiac complications, remains an important benchmark yet to be definitively improved upon. This brief review explores recent adva...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888257/ https://www.ncbi.nlm.nih.gov/pubmed/33614504 http://dx.doi.org/10.3389/fonc.2020.624573 |